Platform includes large library of existing capsids, which have been optimized for performance and targeting across a range of application areas through.
StrideBio Expands Leadership Team with Accomplished Industry Executives streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
RESEARCH TRIANGLE PARK –StrideBio, an emerging startup focusing on gene therapies, is gearing up for more growth after closing on a big $81.5 million round of venture capital.
Backed by Hatteras Venture Partners in Durham, StrideBio announced the new, second round of cash early Tuesday. The round was oversubscribed, the company says.
In 2018, StrideBio raised nearly $16 million in an oversubscribed first round of funding.
The new funding comes after StrideBio struck a $48 million licensing deal with rare disease drugmaker Sarepta Therapeutics in 2019.
Sapan Shah, a 20-year life science industry veteran, was named StrideBio’s CEO that same year.
“We are very pleased to receive such tremendous support from these top-tier healthcare investors and appreciate the confidence they have placed in our entire team,”Shah said of the new funding. “With this additional funding secured we will be able to translate next generation gene therapies enabled by our lead engineered capsid